Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for patients suffering from autoimmune diseases. Guided by our core values, Stay True to Why, Collaborate to Accelerate, Lead with Clarity, Boldly Innovative, and Own the Outcome, we are committed to transforming the future of treatment for autoimmune disease. Join us at the forefront of cell therapy innovation and help redefine what’s possible.
Position Overview
Kyverna is seeking Director, CAR T Channel Strategy & Operations. The Director, CAR T Channel Strategy & Operations is responsible for the development, execution, and continuous improvement of the commercial channel infrastructure supporting CAR T therapy delivery. This role provides strategic leadership for distribution, third-party logistics (3PL), specialty pharmacy strategy, state licensing, government pricing support, and channel governance activities. The position partners closely with Market Access, Commercial, Finance, Legal, Compliance, and Supply Chain teams to ensure scalable, compliant, and customer-focused channel operations that support current and future CAR T commercialization efforts.
Department: Commercial
Location: Remote eligible
Reports To: VP, Global Market Access
Responsibilities
- Develop and execute channel strategies that balance customer experience, operational efficiency, compliance requirements, and gross-to-net (GTN) optimization.
- Serve as business owner for third-party logistics (3PL) partnerships and distribution operations supporting CAR T commercialization.
- Lead specialty pharmacy and distribution strategy development to support current and future portfolio needs.
- Partner with Market Access, Finance, Commercial, and Legal teams to evaluate channel design alternatives and their impact on GTN performance.
- Assess channel economics and recommend strategies that optimize reimbursement, contracting, distribution costs, and commercial profitability while maintaining customer satisfaction.
- Oversee state licensing strategy, renewals, compliance requirements, and regulatory readiness.
- Support government pricing activities through cross-functional coordination, process governance, and operational oversight.
- Lead distribution governance, service-level management, and operational performance reviews across external partners.
- Support launch planning, market expansion, and new product introductions through scalable channel infrastructure.
- Develop reporting, analytics, and performance metrics that provide visibility into channel effectiveness and operational health.
- Identify and mitigate operational, regulatory, and commercial risks across the distribution network.
Qualifications
- Bachelor’s degree required; advanced degree preferred.
- 10+ years of experience in biotechnology, pharmaceutical, specialty distribution, market access, commercial operations, or related functions.
- Experience developing and executing channel strategies for specialty pharmaceuticals, cell therapies, gene therapies, or other complex therapies.
- Strong understanding of gross-to-net (GTN) principles, channel economics, distribution agreements, and commercial contracting.
- Demonstrated ability to design channel solutions that optimize GTN performance while meeting customer, provider, and patient requirements.
Kyverna Therapeutics Emeryville, California, USA Office
5980 Horton St, Suite 550, Emeryville, CA, United States, 94608
Similar Jobs
What you need to know about the San Francisco Tech Scene
Key Facts About San Francisco Tech
- Number of Tech Workers: 365,500; 13.9% of overall workforce (2024 CompTIA survey)
- Major Tech Employers: Google, Apple, Salesforce, Meta
- Key Industries: Artificial intelligence, cloud computing, fintech, consumer technology, software
- Funding Landscape: $50.5 billion in venture capital funding in 2024 (Pitchbook)
- Notable Investors: Sequoia Capital, Andreessen Horowitz, Bessemer Venture Partners, Greylock Partners, Khosla Ventures, Kleiner Perkins
- Research Centers and Universities: Stanford University; University of California, Berkeley; University of San Francisco; Santa Clara University; Ames Research Center; Center for AI Safety; California Institute for Regenerative Medicine
